Zuellig Pharma Strengthens Consumer Healthcare Portfolio with the Acquisition of Zam-Buk® and Vapex® Brands from Bayer

Zuellig Pharma, an industry leader in healthcare solutions in Asia, has just made an exciting announcement. On February 9, 2026, the company declared that it has acquired all rights, title, and interest in and to the Zam-Buk® and Vapex® consumer healthcare brands from Bayer Consumer Care AG for Thailand, Singapore, Indonesia, Malaysia, and Brunei. This strategic acquisition is set to strengthen Zuellig Pharma’s consumer healthcare portfolio and further establish its position as a key player in the region.

The Zam-Buk® and Vapex® brands are well-known and trusted names in the consumer healthcare industry, with a strong presence in the five countries mentioned above. Both brands have a rich history and have been providing effective solutions for common health ailments for decades. With this acquisition, Zuellig Pharma is set to continue and enhance the legacy of these brands while bringing even more value to consumers.

The Managing Director of Zuellig Pharma, Mr. John Graham, expressed his excitement about the acquisition, stating, “We are thrilled to add these two iconic brands to our portfolio. This move aligns perfectly with our mission to provide accessible and quality healthcare solutions to the people of Asia. We are committed to maintaining the trust and confidence that consumers have in Zam-Buk® and Vapex®, and look forward to growing and expanding their reach further.”

Zuellig Pharma has a deep understanding of the healthcare landscape in Asia and has been successfully operating in the region for over 100 years. The company has a strong distribution network that covers over 13 countries, making it an ideal partner for the distribution of Zam-Buk® and Vapex® products. With this acquisition, Zuellig Pharma is set to bring these trusted brands to even more consumers in the region, providing them with top-quality healthcare solutions.

The acquisition of Zam-Buk® and Vapex® is also a testament to Zuellig Pharma’s commitment to continuously expand its portfolio and bring innovative solutions to the market. The company is constantly seeking opportunities to enhance its offerings and meet the evolving needs of consumers. Through this acquisition, Zuellig Pharma is not only adding well-established brands to its portfolio but also showcasing its dedication to providing a diverse range of healthcare products to consumers.

Bayer, the previous owner of Zam-Buk® and Vapex®, has also expressed its confidence in Zuellig Pharma’s capabilities to take these brands to new heights. The CEO of Bayer Consumer Care AG, Ms. Julia Grosse, shared, “We are pleased to have found such a strong and experienced partner in Zuellig Pharma. We are confident that the company will continue to build upon the success of Zam-Buk® and Vapex® and bring them to even greater heights in the region.”

The acquisition of Zam-Buk® and Vapex® is a significant milestone for Zuellig Pharma and reinforces its position as a leading healthcare solutions provider in Asia. The company has long been committed to improving the health and well-being of people in the region, and this acquisition is another step towards achieving this goal.

In conclusion, the acquisition of Zam-Buk® and Vapex® by Zuellig Pharma marks an exciting new chapter for these brands and the company. With its extensive experience, strong distribution network, and commitment to innovation, Zuellig Pharma is poised to take these brands to new heights and provide even more value to consumers in Thailand, Singapore, Indonesia, Malaysia, and Brunei. This is undoubtedly a positive development for the healthcare industry in Asia, and we can expect to see even more great things from Zuellig Pharma in the future.